Akeso, Inc. (HKG:9926)
83.85
-8.95 (-9.64%)
Oct 22, 2026, 3:05 PM HKT
Akeso Employees
Akeso had 4,082 employees as of June 30, 2026. The number of employees increased by 321 or 8.53% since the number was reported on December 31, 2025. That makes Akeso the 6,519th largest employer in the world and 513th in Hong Kong.
Employees
4,082
Change
321
Growth
8.53%
Revenue / Employee
975.85K HKD
Profits / Employee
-273.53K HKD
Market Cap
78.91B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 4,082 | 321 | 8.53% |
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| Innovent Biologics | 8,754 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
Akeso News
- 2 days ago - Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab - PRNewsWire
- 9 days ago - Akeso Doses First Patient In Phase 3 Cadonilimab Study For MSI-H Colon Cancer - Nasdaq
- 10 days ago - Akeso announces first patient dosed in Phase III study of cadonilimab - TheFly
- 22 days ago - AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows - South China Morning Post
- 24 days ago - Akeso Enrolls First Patient In Phase 3 Cadonilimab Head-To-Head Gastric Cancer Trial - Nasdaq
- 24 days ago - Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer - PRNewsWire
- 4 weeks ago - Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals - CNBC
- 5 weeks ago - Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate - PRNewsWire